BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics, Inc. (“Eidos”) (formerly Nasdaq: EIDX) common stock that BridgeBio did not already own. The transaction was overwhelmingly approved by BridgeBio and Eidos stockholders.
Read the full article: BridgeBio Pharma, Inc. Announces Completion of Merger with Eidos Therapeutics, Inc. //
Source: https://www.globenewswire.com/news-release/2021/01/26/2164285/0/en/BridgeBio-Pharma-Inc-Announces-Completion-of-Merger-with-Eidos-Therapeutics-Inc.html